Antihypertensive efficacy of amlodipine in children with chronic kidney diseases
|
|
- Camron George
- 6 years ago
- Views:
Transcription
1 (2001) 15, Nature Publishing Group All rights reserved /01 $ ORIGINAL ARTICLE Antihypertensive efficacy of amlodipine in children with chronic kidney diseases RO von Vigier, LMD Franscini, NDF Bianda, R Pfister, C Casaulta Aebischer and MG Bianchetti Division of Nephrology, University Children s Hospital, Inselspital, Bern, Switzerland In adults the calcium antagonist amlodipine given once a day has proved to be an attractive addition to the antihypertensive armamentarium. The present report describes our experience in 43 paediatric outpatients (26 boys and 17 girls, aged between 1.1 and 19, median 9.8 years) with chronic kidney diseases. The patients were given amlodipine for 16 weeks as part of their antihypertensive treatment. Before amlodipine arterial pressure was 150 ( )/90 (84 95) mm Hg (median and interquartile range). Six patients withdrew from amlodipine because of oedema, flushing or headache. In the remaining patients amlodipine 7.7 ( ) mg/m 2 body surface area once a day significantly decreased arterial pressure by 17 (13 22)/10 (7 13) mm Hg. The efficacy of amlodipine was more pronounced in girls than in boys. No changes in heart rate, body weight and circulating haemoglobin, sodium, potassium and creatinine were noted. In none of the patients circulating potassium, sodium or creatinine changed by more than 0.5 mmol/l, 5 mmol/l respectively 20%. In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial. In conclusion the present experience in paediatric outpatients with chronic kidney diseases supports the view that amlodipine is an effective and rather well tolerated antihypertensive drug when given once a day. (2001) 15, Keywords: amlodipine; calcium antagonist; childhood; kidney diseases Introduction In adults the calcium antagonist amlodipine has assumed an important role in therapeutics of arterial hypertension. 1 4 The success and widespread use of this dihydropyridine derivative is mainly related to its unique pharmacokinetic profile. 5 7 Amlodipine is a low-clearance, hepatically metabolised drug with high oral bioavailability. As would be expected from these data, amlodipine can be administered once a day with very limited interdose fluctuations in antihypertensive effect. In addition the pharmacokinetics indicates that the clearance of amolodipine is unchanged in kidney diseases. Finally the mentioned features suggest that amlodipine has a reduced propensity to cause side effects which result from rapid onset of vasodilatation such as flushing, headache and dizziness and may therefore enhance patient adherence to prescribed medications. 8 In paediatric patients antihypertensive drugs are not investigated prior to approval for marketing in adulthood and information is mostly obtained dur- Correspondence: MG Bianchetti, University Children s Hospital, Inselspital, CH-3010 Bern, Switzerland mario.bianchetti insel.ch Received 3 December 2000; revised and accepted 13 February 2001 ing clinical use, with initial doses determined by extrapolation from adult doses The objective of the present report is to describe our prospective experience in children with chronic kidney diseases who were administered amlodipine for 16 weeks as part of their pharmacological treatment of arterial hypertension. The report includes 16 patients enrolled in a trial published in part earlier. 12 Patients and methods Forty-three Caucasian patients (26 male and 17 female subjects, aged between 1.1 and 19, median 9.8 years) on ambulatory follow-up at the Division of Nephrology, Department of Pediatrics, University of Bern, Switzerland, were prospectively evaluated between 1992 and The underlying conditions were glomerular diseases (n = 19), urinary tract malformations (n = 8), polycystic kidney disease (n = 3), renal artery stenosis (n = 3), interstitial nephritis (n = 1), renal hypoplasia (n = 1) and renal transplant (n = 8). Renal function was either normal (normal plasma creatinine for age and gender, n = 18), mildly reduced (plasma creatinine increased but less than 177 mol/l; n = 12) or moderately reduced (plasma creatinine ranging between 178 and 354 mol/l, n = 5). 13 Eight patients were on regular dialysis (haemodialysis, n = 3; home peritoneal dialysis, n =
2 388 5). In the 43 patients sitting arterial pressure was persistently above the centile 95 for body length and gender. 14 Arterial hypertension was either mild (systolic value up to 19 mm Hg or diastolic value up to 9 mm Hg above centile 95; n = 14), moderate (systolic value 20 to 39 mm Hg or diastolic value 10 to 19 mm Hg above centile 95, n = 22) or severe (systolic value more than 39 mm Hg or diastolic value more than 19 mm Hg above centile 95, n = 7). 15 Sixteen of the 43 patients, subsequently reported to as pretreated, were on medication with a variety of antihypertensive agents: diuretics, n = 6; enalapril, n = 4; perindopril, n = 1; diuretics associated with enalapril, n = 5. The regularly scheduled antihypertensive regimen had not been changed for at least 4 weeks and was continued during treatment with amlodipine. The remaining 27 patients, subsequently reported to as unpretreated, were not on antihypertensive drugs. Arterial pressure, heart rate and body weight were measured and blood taken for the determination of haemoglobin, sodium, potassium, creatinine, aminotranferases and creatine kinase from each patient before entering the trial and 16 weeks after amlodipine (respectively immediately before withdrawing amlodipine). The whole blood cyclosporine trough-level was measured using a specific monoclonal fluorescent polarisation immunoassay in the patients treated with this agent. Patients were monitored by a written questionnaire before and during amlodipine for the presence of abdominal pain, constipation, cough, diarrhoea, dizziness, oedema, fatigue, headache, insomnia, nausea and rash. Amlodipine was started at a once a day dose of 2.5 (body weight ranging between 10 and 30 kg) or 5 mg (body weight 31 kg or more) on awakening. The dose was then increased (up to no more than 0.5 mg/kg body weight respectively 20 mg) if necessary: (a) failure to decrease systolic arterial pressure 5 mm Hg or more 3 to 4 weeks after amlodipine, or (b) systolic arterial pressure above the centile 95 for body length and gender 6 to 8 weeks after amlodipine. Sitting ( 10 min) arterial pressure (first and fifth sound) was measured after overnight by means of a mercury sphygmomanometer with a cuff covering approximately three quarters of the upper arm length from the acromion to the olecranon; each recorded value was the mean of at least three consecutive measurements. The arterial pressure response to amlodipine was evaluated 24 h postdose. Adherence to prescribed amlodipine was assessed by pill count and pharmacy records. The study protocol had been approved by the local ethical committee and by the participants. The results are given as median and interquartile range. Nonparametric analysis of variance for repeated measurements, the McNemar change test (with the Yates correction for continuity) and simple regressions with the coefficient of correlation r s were used for analysis. A P value below 0.05 was regarded as statistically significant. Results Before amlodipine arterial pressure was 150 ( )/90 (84 95) mm Hg and heart rate 77 (74 83) beats/min in the 43 patients enrolled in the trial. The written questionnaire disclosed adverse clinical events in 10 patients before (six male and four female subjects, aged between 5.0 and 17, median 11 years) and in 17 during (eight male and nine female subjects, aged between 3.2 and 17, median 8.4 years) amlodipine (P 0.05), as given in Table 1. The frequency of abdominal pain, constipation, cough, diarrhoea, dizziness, fatigue, insomnia, nausea and rash was similar before and with amlodipine, that of oedema and headache significantly increased on amlodipine. Consequently six patients (two boys and four girls, aged 3.2 to 17, median 11 years) withdrew from amlodipine because of oedema (n = 2), oedema and headache (n = 2). or headache (n = 2). The remaining adverse events were not relevent. Consequently no more than 37 patients (86%) brought the trial to completion. The laboratory safety values (aminotransferases and creatinine kinase) were similar before and during amlodipine. At the end of the 16-week treatment phase the use of amlodipine was associated with a significant (P 0.005) decrease in arterial pressure by 17 (13 22)/10 (7 13) mm Hg (Table 2). The antihypertensive efficacy of amlodipine was more pronounced (P 0.05) in girls (19 (15 213)/11 (8 13) mm Hg) than in boys (16 (12 20)/9 (6 12) mm Hg). The influence of amlodipine on arterial pressure was similar in the 23 unpretreated (16 (13 21)/10 (7 12) mm Hg) and in the 14 pretreated patients (18 (11 22)/9 (7 12) mm Hg) who brought the study to completion. At Table 1 Adverse clinical experiences and laboratory safety values before and with amlodipine in 43 paediatric patients with chronic kidney diseases (26 male and 17 female subjects, aged 1.1 to 19, median 9.8 years). Some adverse experiences concurrently occurred in the same patient Before With P value amlodipine amplodipine (n) (n) All events Abdominal pain 1 1 NS Constipation 2 4 NS Cough 2 2 NS Diarrhoea 2 1 NS Dizziness 2 2 NS Oedema Fatigue 3 3 NS Headache Insomnia 2 2 NS Nausea 0 0 NS Rash 0 1 NS Pathologically increased Alanine aminotransferase 2 1 NS Aspartate aminotransferase 1 1 NS Creatine kinase 2 2 NS NS, not significant.
3 Table 2 Clinical and laboratory values before and with amlodipine in 37 paediatric patients with chronic kidney diseases (24 male and 13 female subjects, aged 1.1 to 19, median 9.0 years) who brought the study to completion. The results are as given as median and interquartile range 389 Before amlodipine With amlodipine P value Arterial pressure, absolute value systolic (mm Hg) 150 ( ) 136 ( ) diastolic (mm Hg) 91 (84 95) 81 (78 85) Arterial pressure, above centile 95 a systolic (mm Hg) 32 (19 46) 16 (10 24) diastolic (mm Hg) 12 (8 15) 2 ( 2 7) Heart rate (beats/min) 79 (74 83) 81 (73 88) NS Body weight (kg) 33 (24 50) 37 (24 50) NS Blood haemoglobin (g/l) 124 ( ) 125 ( ) NS Plasma creatinine ( mol/l) 75 (58 83) 75 (65 85) NS Plasma sodium (mmol/l) 138 ( ) 136 ( ) NS Plasma potassium (mmol/l) 4.2 ( ) 4.2 ( ) NS a For gender, age and height. NS, not significant. that time both systolic and diastolic arterial pressure were below centile 95 in 12 of the 37 patients who completed the study. The initial amlodipine dosage of 0.13 ( ) mg/kg once a day had been subsequently increased up to 0.26 ( ) mg/kg once a day (corresponding to 7.7 ( ) mg/m 2 body surface area). No significant changes in heart rate, body weight and circulating haemoglobin, sodium, potassium and creatinine were noted. In none of the patients plasma potassium, sodium or creatinine levels changed by more than 0.5 mmol/l, 5 mmol/l respectively 20%. The antihypertensive effect of amlodipine (17 (12 22)/10 (7 13) vs 18 (13 21)/9 (7 11) mm Hg) and its dose (0.27 ( ) vs 0.25 ( ) mg/kg body weight once a day) were similar in 15 patients with normal and in 22 with reduced renal function who brought the study to completion. Linear regression analysis disclosed a significant inverse relationship between patient age and final amlodipine dose, expressed in mg/kg body weight daily (Figure 1). No significant correlation was demonstrated between patient age and amlodipine dose, expressed in mg/m 2 body surface area daily (Figure 2). Further regression analysis failed to demonstrate a significant relationship between amlodipine dose, expressed either as mg/kg body weight daily or as mg/m 2 body surface area daily, and change in arterial pressure. Finally no significant correlation was noted between patient age and the influence of amlodipine on arterial pressure. In the patients treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial, as shown in Table 3. Discussion The L-type voltage gated calcium channels are responsible for vascular smooth muscle contractility and myocardial contractility. 16 Acting on the mentioned channels the dihydropyridines are potent vasodilators with little or no effect upon cardiac Figure 1 Relationship between patient age and dose of amlodipine in mg/kg body weight daily in 37 paediatric patients with chronic kidney diseases (24 male and 13 female subjects, aged 1.1 to 19, median 9.0 years). contractility. 16,17 Based upon half-life and effect on myocardial contractility these agents are divided into three categories: 16,17 the short-acting (such as standard nifedipine), the longer-acting formulations with little cardiac depressant activity (such as slow release nifedipine, felodipine, isradipine and nicardipine) and the long-acting agents with no cardiac depressant activity (such as amlodipine). The present experience indicates that amlodipine given once a day in a dose of approximately 7 to 10 mg/m 2 body surface area is an effective treatment for the long term management of mild to severe arterial hypertension in children with chronic kidney diseases. Females show a geater response to this dihydropyridine than males. 1 3 In this study younger patients required significantly higher doses per kilogram of body weight than older children, as previously noted by others. 18 No significant relationship was demonstrated, how-
4 390 Figure 2 Relationship between patient age and dose of amlodipine in mg/m 2 body surface area daily in 37 paediatric patients with chronic kidney diseases (24 male and 13 female subjects, aged 1.1 to 19, median 9.0 years). Table 3 Dosage and blood concentration of cyclosporine levels in 11 pediatric patients (six boys and five girls, aged between 2.9 and 17, median 11 years) with chronic kidney diseases before and during treatment with amlodipine. Results are given as median and interquartile range Before With P value amlodipine amlodipine Cyclosporine dosage 4.9 ( ) 5.0 ( ) NS (mg/kg) a Cyclosporinemia 115 (88 153) 121 (99 161) NS ( g/l) a Given in two daily doses. NS, not significant. ever, between amlodipine dose and patient age when the dosage was expressed as mg/m 2 body surface area. This observation confirms the traditional assumption that dosage schedules based on body surface area are a more reliable guide for the calculations of dosages than those based on body weight. 11,19 The side effects noted in our paediatric patients given amlodipine are similar to those reported in adults and children treated with amlodipine or other dihydropyridines. 1 4,18,20 23 These vasodilators lead in 10 to 20% of patients to one or more of the following: headache, dizziness or lightheadedness, flushing, and peripheral oedema. The peripheral oedema is related to redistribution of fluid from the vascular space into the interstitium, possibly induced by vasodilatation which allows more of the arterial pressure to be transmitted to the capillary circulation. 8 Females appear more susceptible to this adverse effect of dihydropyridines than males. 8 Furthermore, concomitant medication with converting enzyme inhibitors might counter the tendency towards peripheral oedema induced by calcium antagonists. 8 Our patients who developed peripheral oedema and headache on amlodipine discontinued the agent, as previously reported by others. Instead, amlodipine dose reduction was recently suggested. 18 Finally in patients given calcium antagonists acute vasodilatation can enhance sympathetic activity resulting in an increase in heart rate. This change is primarily observed with the short acting, but not with the long-acting dihydropyridine amlodipine. 1 4,16,17 The catabolism of cyclosporine is modified by the concomitant use of the calcium antagonists verapamil and diltiazem, which significantly increase cyclosporine levels. Cyclosporine levels during amlodipine treatment have been so far evaluated in at least eight studies, as recently reviewed. 24 Our observations support the literature and suggest that the effect of amlodipine on the cyclosporine biotransformation is not as great as that seen with verapramil or diltiazem. Amlodipine offers some practical advantages over other dihydropyridine derivatives, which are relevant for treating arterial hypertension in children with chronic kidney diseases. Unlike nifedipine, amlodipine is formulated as a non-sustained release tablet, that can be divided (or dissolved in a liquid preparation) without destroying the integrity of the dosage form. 25 In addition the practice to give drugs once a day provides a convenient dosing schedule that helps to improve adherence to prescribed medications. Finally dose adjustment is superfluous in renal impairment. 1 4,16,17 Paediatric use of amlodipine has previously been reported, 12,18,20 23 but previous reports have been limited by small patient numbers 12,20 23 and rather heterogenous patient populations, that included both in- and outpatients 18,20 or both renal and non renal hypertension. 12,18,20,21 In conclusion the results of the present experience in paediatric outpatients with chronic kidney diseases support the view that amlodipine is an effective and rather well tolerated antihypertensive drug when given once a day in a dosage of 7 to 10 mg/m 2 body surface area and suggest that it has obvious advantages over other dihydropyridines. 26 References 1 Tyler HM. Amlodipine: an effective once-daily antihypertensive agent. J Hum Hypertens 1991; 5 (Suppl 1): Kaplan NM. Amlodipine in the treatment of hypertension. Postgrad Med J 1991; 67 (Suppl 5): S15 S19. 3 Clavijo GA, de Clavijo IV, Weart CW. Amlodipine: a new calcium antagonist. Am J Hosp Pharm 1994; 51: Staessen JA et al. Efficacy of antihypertensive drugs given once a day: the calcium antagonists revisited. J Hypertens Suppl 1994; 12: S107 S Reid JL, Meredith PA, Donnelly R, Elliott HL. Pharmacokinetics of calcium antagonists. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S22 S26. 6 Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J 1989; 118:
5 7 Meredith PA, Elliott HL. Amlodipine; clinical relevance of a unique pharmacokinetic profile. J Cardiovasc Pharmacol 1993; 22 (Suppl A): S6 S8. 8 Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996; 15: Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998; 316: Blumer JL. Off-label drug use in children. Pediatrics 1999; 104: Christensen ML, Helms RA, Chesney RW. Is pediatric labeling really necessary? Pediatrics 1999; 104: Pfammatter JP et al. Amlodipine once-daily in systemic hypertension. Eur J Pediatr 1998; 157: Schwartz GJ, Haycock GB, Spitzer A. Plasma creatinine and urea concentration in children: normal values for age and sex. J Pediatr 1976; 88: High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents. Pediatrics 1996; 98: Guidlines Subcommittee World Health Organization International Society of Hypertension Guidelines for the Management of Hypertension. Blood Press Suppl 1999; 1: Noll G, Lüscher TF. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade. Cardiology 1998; 89 (Suppl 1): Scholz H. Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther 1997; 10 (Suppl 3): Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens 2000; 13: Crawford JD, Terry ME, Rourke GM. Simplification of drug dosage calculation by application of the surface area principle. Pediatrics 1950; 5: Khattak S et al. Efficacy of amlodipine in pediatric bone marrow transplant patients. Clin Pediatr (Phila) 1998; 37: Silverstein DM et al. Use of calcium-channel blockers in pediatric renal transplant recipients. Pediatr Transplant 1999; 3: Tallian KB et al. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol 1999; 13: Rogan JW et al. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol 2000; 14: Schrama YC, Koomans HA. Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function. J Hypertens 1998; 16 (Suppl 6): Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc (Wash) 1999; 39: Flynn JT, Pasko DA. Calcium channels blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 2000; 15:
IJBCP International Journal of Basic & Clinical Pharmacology. Adverse drug effects monitoring of amlodipine in a tertiary care hospital
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20182069 Original Research Article Adverse drug
More informationStudy of the Side effects profile of different antihypertensive drugs among the Hypertensive patient
Study of the Side effects profile of different antihypertensive drugs among the Hypertensive patient Shrestha RK 1, Khan GM 1, Thapa P 1, Koju R 2 1 Department of Pharmacy, Kathmandu University 2 Department
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 January 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 January 2008 ZANIDIP 10mg, film-coated tablets B/28 (CIP: 347 638.7) B/30 (CIP: 372 259.6) B/90 (CIP: 372 260.4)
More informationJMSCR Vol 05 Issue 03 Page March 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.219 Comparative Study of Adverse Effect of
More informationPRESCRIPTION PATTERN OF ANTI HYPERTENSIVE DRUGS IN SHRI SATHYA SAI MEDICAL COLLEGE & RESEARCH INSTITUTE
Original Article PRESCRIPTION PATTERN OF ANTI HYPERTENSIVE DRUGS IN SHRI SATHYA SAI MEDICAL COLLEGE & RESEARCH INSTITUTE Annamalai Maduram 1, Harikrishna 2 INTRODUCTION High blood pressure, termed "hypertension,"
More informationPublic Assessment Report Scientific discussion. Perindopril tert-butylamine/amlodipine Stada (perindopril and amlodipine) SE/H/1500/01-04/DC
Public Assessment Report Scientific discussion Perindopril tert-butylamine/amlodipine Stada (perindopril and amlodipine) SE/H/1500/01-04/DC This module reflects the scientific discussion for the approval
More informationSynopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets
Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study
More informationSUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE
More informationPATIENT INFORMATION LEAFLET ACCEL-AMLODIPINE. Amlodipine Tablets 5 mg and 10 mg amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent
PATIENT INFORMATION LEAFLET Pr ACCEL-AMLODIPINE Amlodipine Tablets 5 mg and 10 mg amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent ACTION AND CLINICAL PHARMACOLOGY ACCEL-AMLODIPINE
More informationTolerance and safety of enalapril
Br. J. clin. Pharmac. (1984), 18, 249S-253S Tolerance and safety of enalapril W. McFATE SMITH, R. 0. DAVIES, M. A. GABRIEL, D. M. KRAMSCH, F. MONCLOA, JANET E. RUSH & J. F. WALKER Merck Sharp & Dohme Research
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amodip 1.25 mg chewable tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Active substance:
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers
More informationFortekor 5 mg. Tablets for Dogs and Cats
Date: 9 April 2003 Page: 1 of 7 Carton, main panel PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY Info pest Verified Fortekor 5 mg Tablets for Dogs and Cats Active Constituent:
More information1 INDICATIONS AND USAGE. 1.1 Hypertension FULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMLODIPINE besylate tablets USP safely and effectively. See full prescribing information for AMLODIPINE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Amlodipine Bluefish 5 mg tablets Amlodipine Bluefish 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains
More informationOne Amlodipine KRKA 5 mg or 10 mg tablet contains amlodipine maleate equivalent to either 5 mg or 10 mg amlodipine per tablet.
1. NAME OF THE MEDICINAL PRODUCT Amlodipine KRKA 5 mg tablets Amlodipine KRKA 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One Amlodipine KRKA 5 mg or 10 mg tablet contains amlodipine maleate
More informationPatients. Excludes paediatrics, neonates.
Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All
More informationNew Zealand Data Sheet. Apo-Amlodipine
New Zealand Data Sheet Apo-Amlodipine Presentation APO-AMLODIPINE 2.5mg are white to off-white, round unscored tablets, engraved APO on one side and AML over 2.5 on the other side. Each tablet typically
More informationAssessing antihypertensive adherence with therapeutic drug monitoring Erika SW JONES, Maia LESOSKY, Marc BLOCKMAN, Sandra CASTEL, Eric H DECLOEDT,
Assessing antihypertensive adherence with therapeutic drug monitoring Erika SW JONES, Maia LESOSKY, Marc BLOCKMAN, Sandra CASTEL, Eric H DECLOEDT, Sylva LU SCHWAGER, Edward D STURROCK, Lubbe WIESNER, Brian
More informationNL/H/880/01-02 FINAL SMPC
SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Amlodipine ratiopharm tablets 5 mg, tablets Amlodipine ratiopharm tablets 10 mg, tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationNon-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without
May 2013 Contents About NSAIDs What about COXselectivity? How effective are NSAIDs? Adverse effects of NSAIDs How frequent are the adverse effects of NSAIDs? General prescribing guidelines for NSAIDs What
More informationDRUG INTERACTIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMLODIPINE BESYLATE TABLETS safely and effectively. See full prescribing information for AMLODIPINE
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion SE/H/1397/01-05/DC Ramipril/Amlodipine Sandoz (ramipril/amlodipine) Applicant: Sandoz A/S This module reflects the scientific discussion for the approval
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Amlodipine 10 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg Amlodipine as Amlodipine Besilate. For
More informationPage 1 of 21. Tablets: 2.5 mg, 5 mg, and 10 mg (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMLODIPINE BESYLATE TABLETS safely and effectively. See full prescribing information for AMLODIPINE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardalis 2.5 mg/20 mg chewable tablets for dogs Cardalis 5 mg/40 mg chewable tablets for dogs Cardalis 10 mg/80
More informationsingle intravenous and oral doses and after 14 repeated oral
Br. J. clin. Pharmac. (1986), 22, 21-25 The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily J. K. FAULKNER
More informationRENT THERAPEUTIC RESEARC~ VOLUME 66, NUMBER 2, MARcH/APRIL 2005
RENT THERAPEUTIC RESEARC~ VOLUME 66, NUMBER 2, MARcH/APRIL 2005 Bioavailability Study of Fixed-Dose Tablet Versus Capsule Formulation of Amlodipine Plus Benazepril: A Randomized, Single-Dose, Two-Sequence,
More informationMetacam. The Only NSAID Approved for Cats in the US. John G. Pantalo, VMD Professional Services Veterinarian. Think easy. Think cat. Think METACAM.
Metacam The Only NSAID Approved for Cats in the US John G. Pantalo, VMD Professional Services Veterinarian Think easy. Think cat. Think METACAM. Today s Agenda New pain management guidelines for cats Only
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Amlotan 5 and 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Amlotan 5 mg tablets: Each tablet contains 5 mg amlodipine (as
More informationThe 4 th Generation calcium channel blocker C I L N I D I P I N E
T The 4 th Generation calcium channel blocker C I L N I D I P I N E = TOp DUal Action New Ca 2+ Channel Blocker Cilnidipine (IHS) - C 27 H 28 N 2 O 7 INDICATION Essential Hypertension DOSAGE & PACKAGE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardalis 2.5 mg/20 mg tablets for dogs Cardalis 5 mg/40 mg tablets for dogs Cardalis 10 mg/80 mg tablets for dogs
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT FORTEKOR PLUS 1.25 mg/2.5 mg tablets for dogs FORTEKOR PLUS 5 mg/10 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fluclon 250 mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 250mg of flucloxacillin as flucloxacillin sodium.
More informationAMLODIPINE BESYLATE + OLMESARTAN MEDOXOMIL. Dihydropyridine Ca channel blocker [Dhp-CCB] + Angiotensin II receptor blockage [ARB]
AMLODIPINE BESYLATE + OLMESARTAN MEDOXOMIL Dihydropyridine Ca channel blocker [Dhp-CCB] + Angiotensin II receptor blockage [ARB] ESH/ESC HT MANAGEMENT GUIDELINE 2013 DIAGNOSIS TARGET BP TARGET BP CONTROL
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Istolde 10 mg tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 10 mg tablets: Each tablet contains 10 mg amlodipine (as besilate) For
More informationPBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine with Viekirax or Viekira Pak
PBPK/PD Modeling and Simulations to Guide Dose Recommendation of Amlodipine with Viekirax or Viekira Pak Dwaipayan Mukherjee, Ph.D. Jiuhong Zha, Ph.D. Rajeev Menon, Ph.D. Mohamad Shebley, Ph.D. Clinical
More informationJust where it s needed.
Relief. Just where it s needed. Tissue-selective 7,8 Strong safety profile 5,6,10,11 For dogs and cats Onsior is available in a range of convenient and easy-to-dose formulations. Injectable solution for
More information1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 TRADE NAME OF THE MEDICINAL PRODUCT Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2ml contains 20mg of Gentamicin as Gentamicin Sulfate Excipient
More informationmelatonin amlodipine generic for amlodipine benazepril amlodipine angioedema amlodipine feline amlodipine 5 mg description
Follow all directions on your computer even when amlodipine for sale you buy Ambien. Call your doctor or dial 911 immediately. Ativan can cause tolerance, physical dependence, addiction and withdrawal
More informationDr. Omar S. Tabbouche, M.Sc, D.Sc, Pharm.D Head of Pharmacy Department New Mazloum Hospital Tripoli, Lebanon
Efficacy & Safety of Ketoprofen 25mg vs. Paracetamol 1g intravenous preparations in the management of fever in adults: A pilot, double-blind, parallel-group, randomized controlled trial Dr. Omar S. Tabbouche,
More informationOriginal Article. Introduction. Korean Circulation Journal
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Valsartan 160 mg/amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate
More informationFrequently asked questions
Frequently asked questions At what stage of heart failure should Cardalis be used? Cardalis should be given as part of your standard heart failure therapy as soon as clinical signs (such as exercise intolerance,
More informationNorvasc 5 & 10mg tablets
Norvasc 5 & 10mg tablets 1. Name of the medicinal product Norvasc 5& 10 mg Tablets 2. Qualitative and quantitative composition Each tablet contains amlodipine besilate equivalent to 5 and 10mg amlodipine.
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Amlodipine 5 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg Amlodipine as Amlodipine Besilate. For full
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationNL/H/-882/ SUMMARY OF PRODUCT CHARACTERISTICS 1/13
SUMMARY OF PRODUCT CHARACTERISTICS 1/13 1 NAME OF THE MEDICINAL PRODUCT Amlodipine CT 5 mg, tabletten Amlodipine CT 10 mg, tabletten 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Amlodipine ratiopharm tablets
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More information1.3.1 Amlodipine besilate SPC, Labeling and Package Leaflet NL
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT 5 mg tablets 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 5 mg tablets: Each
More informationAMLOPRESS SAJA PHARMA
08-15 AMLOPRESS SAJA PHARMA Amlodipine (as besylate) 5 mg Capsule for Oral Use 1. NAME OF THE MEDICINAL PRODUCT AMLOPRESS 5 mg Capsule 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Capsule contains
More informationSpeciality: Therapeutics
Gentamicin Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission May 2017 Date on which
More informationPATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION. and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION
PATIENT INFORMATION LEAFLET GENTAMICIN 10MG/ML SOLUTION FOR INJECTION OR INFUSION and GENTAMICIN 40MG/ML SOLUTION FOR INJECTION OR INFUSION Read all of this leaflet carefully before you start taking this
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationTreating Rosacea in the Era of Bacterial Resistance. This presentation is sponsored by Galderma Laboratories, L.P.
Treating Rosacea in the Era of Bacterial Resistance This presentation is sponsored by Galderma Laboratories, L.P. Lecture Discuss rosacea as an inflammatory condition Assess the psychosocial impact of
More informationAmlodipine Passage into Breast Milk in Lactating Women with Pregnancy-Induced Hypertension and Its Estimation of Infant Risk for Breastfeeding
56195JHLXXX1.1177/8933441456195Journal of Human LactationNaito et al research-article214 Original Research Amlodipine Passage into Breast Milk in Lactating Women with Pregnancy-Induced Hypertension and
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 10. Treatment of peritoneal dialysis associated fungal peritonitis
10. Treatment of peritoneal dialysis associated fungal peritonitis Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) The use of
More informationPRODUCT MONOGRAPH. amlodipine besylate. Tablets 2.5, 5 and 10 mg. Antihypertensive-Antianginal Agent
PRODUCT MONOGRAPH Pr GD -AMLODIPINE amlodipine besylate Tablets 2.5, 5 and 10 mg Antihypertensive-Antianginal Agent GenMed, a division of Pfizer Canada Inc. 17 300 Trans-Canada Highway Kirkland, Quebec
More informationPRODUCT MONOGRAPH. amlodipine besylate. Tablets 2.5, 5 and 10 mg. Antihypertensive-Antianginal Agent
PRODUCT MONOGRAPH Pr NORVASC amlodipine besylate Tablets 2.5, 5 and 10 mg Antihypertensive-Antianginal Agent PFIZER CANADA INC. 17 300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Revision: September
More informationMaximum antihypertensive effects are attained within 2 weeks after a change in dose. AZOR may be administered with other antihypertensive agents.
Page 4 FULL PRESCRIBING INFORMATION AZOR (amlodipine and olmesartan medoxomil) tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin
More informationSANDOZ AMLODIPINE PRODUCT MONOGRAPH. Amlodipine Besylate. Tablets 2.5 mg, 5 mg and 10 mg. Antihypertensive-Antianginal Agent
PRODUCT MONOGRAPH Pr SANDOZ AMLODIPINE Amlodipine Besylate Tablets 2.5 mg, 5 mg and 10 mg Antihypertensive-Antianginal Agent Sandoz Canada Inc. Date of Revision: 145 Jules Léger December 1, 2017 Boucherville,
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Amlodipine 5 mg Tablets Amlodipine 10 mg Tablets (Amlodipine Besilate)
PACKAGE LEAFLET: INFORMATION FOR THE USER Amlodipine 5 mg Tablets Amlodipine 10 mg Tablets (Amlodipine Besilate) Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More informationCats usually develop secondary hypertension with an
J Vet Intern Med 2015 Randomized Placebo-Controlled Clinical Trial of a Chewable Formulation of Amlodipine for the Treatment of Hypertension in Client-Owned Cats M. Huhtinen, G. Derre, H.J. Renoldi, M.
More informationPRODUCT MONOGRAPH. Pr AMLODIPINE. Amlodipine Besylate Tablets, House Standard. 5 mg and 10 mg. Amlodipine (as amlodipine besylate)
PRODUCT MONOGRAPH Pr AMLODIPINE Amlodipine Besylate Tablets, House Standard 5 mg and 10 mg Amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent JAMP Pharma Corporation Date of Preparation:
More informationPRODUCT MONOGRAPH SANDOZ AMLODIPINE. Amlodipine Besylate. Tablets 2.5 mg, 5 mg and 10 mg. Antihypertensive-Antianginal Agent
PRODUCT MONOGRAPH Pr SANDOZ AMLODIPINE Amlodipine Besylate Tablets 2.5 mg, 5 mg and 10 mg Antihypertensive-Antianginal Agent Sandoz Canada Inc. Date of Revision: 145 Jules Léger September 25, 2015 Boucherville,
More informationAlprim Trimethoprim PRODUCT INFORMATION NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. Active ingredient: Trimethoprim
Alprim Trimethoprim PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Trimethoprim Chemical name: 5-(3,4,5-trimethoxybenzyl)-pyrimidine-2, 4-diamine Structural formula: Molecular formula: C 14
More informationCHEMMART AMLODIPINE 2.5 mg, 5 mg, 10 mg TABLETS
CHEMMART AMLODIPINE 2.5 mg, 5 mg, 10 mg TABLETS Product Information Australia NAME OF THE MEDICINE Amlodipine besylate. DESCRIPTION Amlodipine besylate is a dihydropyridine derivative. Chemical Name: 3-ethyl
More informationIndicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.
Zoetis UK Limited Telephone: 0845 300 8034 Website: www.zoetis.co.uk Email: customersupportuk@zoetis.com Apoquel film-coated for dogs Species: Therapeutic indication: Active ingredient: Product: Product
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Desloratadine Actavis 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg desloratadine.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 16 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pimovita 10 mg chewable tablets for dogs Pimovita vet.10 mg chewable tablets for
More informationDrug monograph of CADUET
Drug monograph of CADUET Generic name: Amlodipine and Atorvastatin Brand name: Caduet Manufacturer: Pfizer Classification: Prescription only medicine Strength (amlodipine mg/ atorvastatin mg): 2.5/10,
More informationApplicant Invented name Strength Pharmaceutical Form
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES. 1 Member State Marketing Authorisation
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 18 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardisure flavoured 10 mg Tablets For dogs (Austria, Belgium, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands,,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Efestad 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg desloratadine. Excipient: 31.5
More informationIntravenous Antibiotic Therapy Information Leaflet
Scottish Adult Cystic Fibrosis Service Ninewells Hospital Dundee Intravenous Antibiotic Therapy Information Leaflet February 2008 Intravenous antibiotic therapy in cystic fibrosis Patients with cystic
More informationProviding Constant Analgesia with OROS Ò Hydromorphone
Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S19 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting
More informationAmlodipine Increases Cyclosporine Levels in Hypertensive Renal Transplant Patients: Results of a Prospective 2
EDITORIAL COMMITIEE Tomas Berl, Editor Denver, CO William Toledo, Henrich OH Mark Paller Minneapolis, MN Fred Silva Oklahoma City, OK THE NEPHROLOGY TRAINING PROGRAM UNIVERSITY OF ALABAMA AT BIRMINGHAM
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) OPINION FOLLOWING AN ARTICLE 29 REFERRAL. Amlovita
European Medicines Agency COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) OPINION FOLLOWING AN ARTICLE 29 REFERRAL Amlovita International Non-Proprietary Name (INN): Amlodipine BACKGROUND INFORMATION*
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationKeywords: Benazepril - Congestive heart failure - Dogs
Long-term tolerability of benazepril in dogs with congestive heart failure Jean-Louis Pouchelon 1 ; Jonathan King; Laure Martignoni; Valérie Chetboul; Béatrice Lugardon; Jean-François Rousselot; Jean-Philippe
More informationPRODUCT MONOGRAPH. Amlodipine Besylate tablets. 2.5 mg, 5 mg & 10 mg (amlodipine as amlodipine besylate) Antihypertensive-Antianginal Agent
PRODUCT MONOGRAPH Pr AMLODIPINE Amlodipine Besylate tablets 2.5 mg, 5 mg & 10 mg (amlodipine as amlodipine besylate) Antihypertensive-Antianginal Agent Sivem Pharmaceuticals ULC 4705 Dobrin Street St.
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT GALLIPRANT 20 mg tablets for dogs GALLIPRANT 60 mg tablets for dogs GALLIPRANT 100 mg tablets for dogs 2. QUALITATIVE
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Amlodipine 10 mg Tablets. (Amlodipine Besilate)
PACKAGE LEAFLET: INFORMATION FOR THE USER Amlodipine 5 mg Tablets Amlodipine 10 mg Tablets (Amlodipine Besilate) Read all of this leaflet carefully before you start taking this medicine because it contains
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cefaseptin 750 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: cefalexin
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 10 Mar 2019 06:52:14 GMT) CTRI Number Last Modified On 29/07/2016 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationAUSTRALIAN PRODUCT INFORMATION AMLO (AMLODIPINE BESILATE) UNCOATED TABLETS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
AUSTRALIAN PRODUCT INFORMATION AMLO (AMLODIPINE BESILATE) UNCOATED TABLETS 1 NAME OF THE MEDICINE Amlodipine besilate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION AMLO contains the active ingredient Amlodipine
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationSrirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.
Indian Medical Gazette JUNE 2015 225 Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid
More informationPRODUCT MONOGRAPH. Septa-Amlodipine Tablets. 2.5mg, 5mg and 10 mg amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent
PRODUCT MONOGRAPH Pr Septa-Amlodipine Tablets 2.5mg, 5mg and 10 mg amlodipine (as amlodipine besylate) Antihypertensive-Antianginal Agent Septa Pharmaceuticals Inc. Date of Preparation 7490 Pacific Circle,
More informationCommunity Acquired Pneumonia: An Update on Guidelines
Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia
More informationAcute Pyelonephritis POAC Guideline
Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice
More informationAmlodipin Bluefish 10 mg tablets. amlodipine
Package leaflet: Information for the user Amlodipin Bluefish 5 mg tablets Amlodipin Bluefish 10 mg tablets amlodipine Read all of this leaflet carefully before you start taking this medicine because it
More informationPrescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children
Prescribing Guidelines for Outpatient Antimicrobials in Otherwise Healthy Children Prescribing Antimicrobials for Common Illnesses When treating common illnesses such as ear infections and strep throat,
More informationAMLODIPINE 5 MG TABLETS AMLODIPINE 10 MG TABLETS Amlodipine
Package Leaflet: Information For The User AMLODIPINE 5 MG TABLETS AMLODIPINE 10 MG TABLETS Amlodipine Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationAnesthesia Check-off Form
Anesthesia Check-off Form 5231 SW 91st Drive Gainesville, FL 32608 (352) 377-6003 The doctors and staff at Haile Plantation Animal Clinic would like to offer the most advanced medical care and services
More informationDevelopment and validation of a HPLC analytical assay method for amlodipine besylate tablets: A Potent Ca +2 channel blocker
Development and validation of a HPLC analytical assay method for amlodipine besylate tablets: A Potent Ca +2 channel blocker Richa Sah* and Saahil Arora 1. ISF College of Pharmacy, Moga, Punjab, India
More information